Cabergoline

Overview

Cabergoline (Dostinex®, Galastop®) is a synthetic ergot-derived dopamine (D2) receptor agonist used in dogs and cats for suppression of prolactin secretion and management of prolactin-dependent reproductive disorders. It has high specificity for D2 receptors and a prolonged duration of action.

By directly inhibiting prolactin release from the anterior pituitary gland, cabergoline reduces luteal support in species where prolactin is luteotrophic, such as dogs and cats. This effect underlies its clinical use in pseudopregnancy, estrus manipulation, medical management of pyometra, and pregnancy termination.

Compared with bromocriptine, cabergoline demonstrates greater D2 receptor selectivity, longer duration of action, and a lower incidence of vomiting, making it generally better tolerated in clinical practice. It is administered orally and may require compounding for accurate dosing in cats and small dogs.

Pharmacokinetics: Specific pharmacokinetic data in dogs and cats are limited. In other species, cabergoline is absorbed after oral administration, widely distributed, moderately protein bound, and extensively metabolized in the liver. The elimination half-life is prolonged (approximately 60 hours), and pharmacologic effects may persist for 48 hours or more. Severe hepatic insufficiency may increase systemic exposure.

Indications

In dogs and cats, cabergoline is used for management of prolactin-dependent and hormonally mediated reproductive disorders. Clinical use should be based on accurate assessment of reproductive stage and overall patient stability.

• Medical management of pyometra: Used as part of a medical treatment protocol in selected, stable patients to reduce luteal support and assist uterine evacuation.
• Induction and synchronization of estrus: May be used to induce estrus or synchronize cycles, particularly in cases of primary or secondary anestrus.
• Treatment of anestrus: Useful in managing prolonged or abnormal interestrous intervals when endocrine evaluation supports therapy.
• Pseudopregnancy (false pregnancy): Reduces clinical signs such as mammary enlargement, lactation, nesting behavior, and maternal aggression.
• Mastitis (adjunctive use): Suppresses prolactin and decreases milk production when lactation reduction is clinically indicated.
• Pre-surgical management for mammary tumors: May be administered prior to mammary tumor surgery to decrease hormonally stimulated mammary activity.
• Pregnancy termination (second half of gestation): Induces abortion due to prolactin suppression and luteal regression when administered during mid to late pregnancy.
• Post-spay behavioral changes: Reported use for aggression or anxiety occurring after ovariohysterectomy, particularly when surgery was performed during the luteal phase.

Dosage (Reference)

Dog

Cabergoline is administered orally in dogs. Dose and duration depend on the indication. Monitoring of clinical response is essential to determine treatment success.

Cat

Cabergoline is administered orally in cats. Accurate dosing may require compounding due to small body size.

Warnings & Precautions

Cabergoline is a dopaminergic agent with significant reproductive and endocrine effects. Careful patient selection and monitoring are required, particularly in breeding animals and those with systemic disease.

• Hypersensitivity to ergot derivatives: Contraindicated in patients with known hypersensitivity to ergot-based medications (e.g., bromocriptine). Patients intolerant to bromocriptine may also not tolerate cabergoline.
• Pregnancy: Contraindicated in pregnant dogs or cats unless pregnancy termination is the intended goal, as prolactin suppression may result in abortion.
• Nursing animals: Suppresses prolactin and milk production; should not be used in lactating dams or queens unless intentional suppression of lactation is desired.
• Hypertension: Use cautiously in patients with hypertension, especially those receiving antihypertensive medications, as additive blood pressure effects or syncope may occur.
• Hepatic disease: Extensively metabolized in the liver; use cautiously in patients with hepatic impairment, as reduced metabolism may increase systemic exposure.
• Estrus induction timing: When used to induce estrus, wait at least 4 months after the previous cycle to allow adequate uterine recovery.
• Occupational safety: Classified as a hazardous drug by the National Institute for Occupational Safety and Health (NIOSH). Appropriate personal protective equipment (PPE) should be used during handling.
• Reproductive handling precautions: Pregnant or nursing women, or women attempting to conceive, should avoid handling the medication due to potential reproductive risks.

Drug Interactions

Clinically relevant interactions with cabergoline are primarily related to dopamine receptor antagonism or additive cardiovascular effects. When combining medications, assess risk–benefit and monitor appropriately.

• Dopamine (D2) antagonists (e.g., metoclopramide, phenothiazines such as acepromazine or chlorpromazine, butyrophenones such as haloperidol):
  Concurrent use may reduce the efficacy of both drugs due to opposing pharmacologic actions and should be avoided.
• Hypotensive drugs (e.g., amlodipine, enalapril, telmisartan):
  Cabergoline may have hypotensive effects; combined use can result in additive hypotension. Avoid concomitant administration or monitor blood pressure closely.
• Macrolide antibiotics (e.g., clarithromycin):
  May increase cabergoline plasma concentrations, potentially enhancing adverse effects.
• Reserpine:
  May increase prolactin concentrations; adjustment of cabergoline dosage may be required.

Side Effects & Overdose

Side Effects

Cabergoline is generally well tolerated in dogs and cats. Most adverse effects are mild and often occur during the first few doses.

• Vomiting: Most commonly reported, particularly during the initial days of therapy; may improve with dose reduction or administration with food.
• Lethargy: Mild decrease in activity level may occur.
• Decreased appetite (hyporexia): Usually transient.
• Coat changes (dogs): Dogs receiving therapy for more than 14 days may exhibit changes in coat color or texture; typically reversible after drug discontinuation.
• Hypotension (theoretical): Based on dopaminergic effects; monitor if clinical signs of weakness or syncope develop.

Overdose

Specific overdose data in dogs and cats are limited. Clinical signs are expected to reflect exaggerated pharmacologic effects of dopaminergic stimulation.

• Hypotension: May result in weakness, collapse, or syncope.
• Neurologic signs: Depression, dizziness, or abnormal behavior; hallucination-like signs are theoretically possible.
• Gastrointestinal effects: Nausea and vomiting may occur; emesis may develop spontaneously.
• Management: Provide supportive care with cardiovascular monitoring (blood pressure, heart rate). Consider GI decontamination if recent ingestion and clinically appropriate.
• Consultation: In suspected or confirmed overdose cases, consultation with a veterinary poison control center is recommended.

Key Notes

Practical clinical considerations to optimize the safe and effective use of cabergoline in dogs and cats:

• Long duration of action: With a prolonged half-life (approximately 60 hours), clinical effects may persist for 48 hours or longer after dosing adjustments.
• Response-based monitoring: Treatment success should be assessed according to the indication (e.g., resolution of pseudopregnancy signs, uterine evacuation, return to estrus), rather than duration alone.
• Progesterone monitoring: Measuring serum progesterone concentrations can help evaluate therapeutic response and confirm client adherence when reproductive control is the goal.
• Better tolerability vs. bromocriptine: Lower incidence of gastrointestinal intolerance makes it a preferred prolactin inhibitor in many patients.
• Compounding considerations: If a liquid formulation is required, lipid-based preparations are preferred for stability; aqueous suspensions should be used immediately and discarded.
• Client handling guidance: Advise owners to use disposable gloves when handling tablets or split doses and to avoid inhaling powder from crushed tablets.
• Storage: Store tablets at controlled room temperature (20–25°C). Veterinary oral solutions should be protected from light and used within 28 days after opening (if applicable).